Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 1;58(19):2839-2843.
doi: 10.2169/internalmedicine.2556-19. Epub 2019 Jun 27.

Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review

Shoko Murakami  1 , Tatsuya Nagano  1 , Kyosuke Nakata  1 , Akira Onishi  2 , Kanoko Umezawa  1 , Naoko Katsurada  1 , Masatsugu Yamamoto  1 , Motoko Tachihara  1 , Kazuyuki Kobayashi  1 , Yoshihiro Nishimura  1
Affiliations
Review

Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review

Shoko Murakami et al. Intern Med. .

Abstract

A 51-year-old man underwent second-line treatment for non-small-cell lung cancer (NSCLC) with the immune checkpoint inhibitor (ICI) pembrolizumab. On day 2 after two cycles of pembrolizumab, he presented with edema limited to the left third, fourth, and fifth fingers. Based on symptoms, laboratory results, and contrast-enhanced magnetic resonance imaging (MRI) findings, we diagnosed him with tenosynovitis. We prescribed oral prednisolone (0.5 mg/kg/day), and pembrolizumab was continued. Prednisolone immediately relieved the symptoms, and the tumor was still shrinking on day 21 after eight cycles of pembrolizumab. ICI-induced tenosynovitis was managed while continuing ICI usage, suggesting that 0.5 mg/kg/day prednisone might be effective for tenosynovitis without ICI cessation.

Keywords: pembrolizumab; prednisolone; tenosynovitis.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure 1.
Figure 1.
Computed tomography (CT) revealed the shrinkage of the primary lesion (arrow) and the right adrenal gland metastasis before pembrolizumab (A and D), after four cycles of pembrolizumab (B and E), and after eight cycles of pembrolizumab (C and F).
Figure 2.
Figure 2.
Short-tau inversion-recovery (STIR) magnetic resonance imaging (MRI) showed high-intensity signals for the tenosynovium of the left third (A, arrow), fourth (B, arrow), and fifth fingers (C, arrow) and the right first finger (D, arrow).
Figure 3.
Figure 3.
The clinical course of the patient.
See this image and copyright information in PMC

References

    1. Haanen JB, Thienen H, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol 42: 423-428, 2015. - PubMed
    1. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 11: 535-542, 2010. - PMC - PubMed
    1. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1: 1223-1225, 2012. - PMC - PubMed
    1. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6: 230ra245, 2014. - PubMed
    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378: 158-168, 2018. - PubMed

MeSH terms